Pulmonary hypertension related to congenital heart disease: A call for action

European Heart Journal

Volumn 35, Issue 11, 2014, Pages

  Dimopoulos, Konstantinos ^a   Wort, Stephen John ^a   Gatzoulis, Michael A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Advanced therapies; Congenital heart disease; Eisenmenger syndrome; Pulmonary hypertension; Pulmonary vascular disease; Targeted therapies; Treat and repair

Indexed keywords

AORTOPULMONARY SEPTAL DEFECT; ATRIOVENTRICULAR SEPTAL DEFECT; CARDIOLOGIST; CLINICAL RESEARCH; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; EISENMENGER COMPLEX; EMERGENCY CARE; ERYTHROCYTOSIS; EXERCISE; FORWARD HEART FAILURE; GALLSTONE; HEART CATHETERIZATION; HEART OUTPUT; HEART SINGLE VENTRICLE; HEART VENTRICLE FUNCTION; HUMAN; IRON DEFICIENCY; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG VEIN DRAINAGE ANOMALY; MORBIDITY; OXYGEN SATURATION; PATENT FORAMEN OVALE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; QUALITY OF LIFE; REVIEW; SUPERIOR CAVA VEIN; TRICUSPID VALVE REGURGITATION;

ADVANCED THERAPIES; CONGENITAL HEART DISEASE; EISENMENGER SYNDROME; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; TARGETED THERAPIES; TREAT AND REPAIR;

ADULT; BIOMEDICAL RESEARCH; CARDIOLOGY; DEVELOPING COUNTRIES; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; EDUCATION, MEDICAL, CONTINUING; EISENMENGER COMPLEX; GENOTYPE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INTERNATIONAL COOPERATION; INTERPROFESSIONAL RELATIONS; MAGNETIC RESONANCE ANGIOGRAPHY; PROGNOSIS; QUALITY OF LIFE;

EID: 84898947341     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht437     Document Type: Review

References (74)

1. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I. Br Med J 1958;2:701-709
2. Engelfriet PM, Duffels MGJ, Mö ller T, Boersma E, Tijssen JGP, Thaulow E, Gatzoulis MA, Mulder BJM. Pulmonary arterial hypertension in adults born with a heart septal defect: The Euro Heart Survey on adult congenital heart disease. Heart Br Card Soc 2007;93:682-687
3. Diller G-P, Dimopoulos K, Broberg CS, KayaMG, Naghotra US, Uebing A, Harries C, Goktekin O, Gibbs JSR, Gatzoulis MA. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: A combined retrospective and case-control study. Eur Heart J 2006;27:1737-1742. (Pubitemid 44025362)
4. Gatzoulis MA. The management of Eisenmenger syndromein the modern treatment era: A case report. Eur Respir Rev 2011;20:293-296
5. Humenberger M, Rosenhek R, Gabriel H, Rader F, Heger M, Klaar U, Binder T, Probst P, Heinze G, Maurer G, Baumgartner H. Benefit of atrial septal defect closure in adults: Impact of age. Eur Heart J 2011;32:553-560
6. Dimopoulos K, Peset A, Gatzoulis M. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008;129:163-171
7. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: A comparison between clinical subgroups. Eur Heart J; doi:10.1093/ eurheartj/eht072. Published online ahead of print 1 March 2013.
8. Dimopoulos K, Diller G-P, Petraco R, Koltsida E, Giannakoulas G, Tay EL, Best N, Piepoli MF, Francis DP, Poole-Wilson PA, Gatzoulis MA. Hyponatraemia: A strong predictor of mortality in adults with congenital heart disease. Eur Heart J 2010;31: 595-601
9. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998;19:1845-1855
10. Wray J, Frigiola A, Bull C, Adult Congenital Heart disease Research Network (ACoRN). Loss to specialist follow-up in congenital heart disease; out of sight, out of mind. Heart Br Card Soc 2013;99:485-490
11. Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R, Vachiéry J-L, Paelinck B, Morissens M, Budts W. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J 2011;32:2790-2799
12. Tay ELW, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez R, Giannakoulas G, Tzifa A, Goletto S, Broberg C, Dimopoulos K, Gatzoulis MA. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011;151:307-312
13. Longmuir PE, Brothers JA, de Ferranti SD, Hayman LL, Van Hare GF, Matherne GP, Davis CK, Joy EA, McCrindle BW, American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Promotion of physical activity for children and adults with congenital heart disease: A scientific statement from the American Heart Association. Circulation 2013;127:2147-2159
14. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol 2008; 52:e143-e263
15. Dimopoulos K, Giannakoulas G,Wort SJ, Gatzoulis MA. Pulmonary arterial hypertension in adults with congenital heart disease: Distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol 2008;23:545-554
16. Perloff JK. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol Clin 1993; 11:689-699
17. Shiina Y, Toyoda T, Kawasoe Y, Tateno S, Shirai T, Matsuo K, Mizuno Y, Ai T, Niwa K. The prevalence and risk factors for cholelithiasis and asymptomatic gallstones in adults with congenital heart disease. Int J Cardiol 2011;152:171-176
18. Dimopoulos K, Diller G-P, Koltsida E, Pijuan-Domenech A, Papadopoulou SA, Babu-Narayan SV, Salukhe TV, Piepoli MF, Poole-Wilson PA, Best N, Francis DP, Gatzoulis MA. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 2008;117:2320-2328. (Pubitemid 351681557)
19. Diller G-P, Lammers AE, Haworth SG, Dimopoulos K, Derrick G, Bonhoeffer P, Gatzoulis MA, Francis DP. A modelling study of atrial septostomy for pulmonary arterial hypertension, and its effect on the state of tissue oxygenation and systemic blood flow. Cardiol Young 2010;20:25-32
20. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, KlepetkoW, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-2537
21. Baim DS. Grossman's Cardiac Catheterization, Angiography, and Intervention. Lippincott Williams & Wilkins; 2006
22. Muthurangu V, Taylor A, Andriantsimiavona R, Hegde S, Miquel ME, Tulloh R, Baker E, Hill DLG, Razavi RS.Novel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flow. Circulation 2004;110:826-834. (Pubitemid 39096011)
23. Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, Kaine SF, Ivy DD, Webber SA, Rothman A, Ross RD, Aggarwal S, Takahashi M, Waldman JD. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): The INOP Test Study Group. Circulation 2002;106:I76-I81
24. Baumgartner H, Bonhoeffer P, De Groot NMS, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJM, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E, Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC), Association for European Paediatric Cardiology (AEPC), ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010;31:2915-2957
25. D'Alto M, Romeo E, Argiento P, Santoro G, Sarubbi B, Gaio G, Mélot C, Russo MG, Naeije R, Calabrò R. Pulmonary vasoreactivity predicts long-Term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart Br Card Soc 2010;96:1475-1479
26. Post MC, Janssens S, Van deWerf F, BudtsW. Responsiveness to inhaled nitric oxide is a predictor for mid-Term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 2004;25:1651-1656
27. Spence MS, Balaratnam MS, Gatzoulis MA. Clinical update: Cyanotic adult congenital heart disease. Lancet 2007;370:1530-1532. (Pubitemid 350027743)
28. Diller G-P, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA. Exercise intolerance in adult congenital heart disease. Circulation 2005;112:828-835
29. Dimopoulos K, Okonko DO, Diller G-P, Broberg CS, Salukhe TV, Babu-Narayan SV, Li W, Uebing A, Bayne S, Wensel R, Piepoli MF, Poole-Wilson PA, Francis DP, Gatzoulis MA. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 2006;113: 2796-2802. (Pubitemid 44305291)
30. Kempny A, Dimopoulos K, Uebing A, Moceri P, Swan L, Gatzoulis MA, Diller G.-P. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life - single centre experience and review of published data. Eur Heart J 2011;33:1386-96
31. Broberg CS, Uebing A, Cuomo L, Thein SL, Papadopoulos MG, Gatzoulis MA. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart Br Card Soc 2007;93:1599-1603. (Pubitemid 350205558)
32. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009;30:256-265
33. European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart J-M, Gibbs JSR, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AHEM, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L, ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147-3197
34. Lovell AT. Anaesthetic implications of grown-up congenital heart disease. Br J Anaesth 2004;93:129-139. (Pubitemid 38967435)
35. Price LC, Montani D, Jaís X, Dick JR, Simonneau G, Sitbon O, Mercier FJ, Humbert M. Noncardiothoracic nonobstetric surgery in mild-To-moderate pulmonary hypertension. Eur Respir J 2010;35:1294-1302
36. Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: Predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005;45:1691-1699. (Pubitemid 40704508)
37. Frescura C, Thiene G, Giulia Gagliardi M, Mazzucco A, Pellegrino PA, Daliento L, Biscaglia S, Carminati M, Gallucci V. Is lung biopsy useful for surgical decision making in congenital heart disease? Eur J Cardio-Thorac Surg 1991;5:118-122; discussion 122-123
38. Wagenvoort CA,Wagenvoort N, Draulans-Noe? Y. Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery. J Thorac Cardiovasc Surg 1984;87:876-886
39. Wagenvoort CA. Morphological substrate for the reversibility and irreversibility of pulmonary hypertension. Eur Heart J 1988;9(Suppl. J):7-12
40. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease - long-Term follow-up and prediction of outcome after surgical correction. Circulation 1987;76:1037-1042. (Pubitemid 17157284)
41. D'Alto M, RomeoE, Argiento P, Correra A, Santoro G, Gaio G, Sarubbi B, Calabrò R, Russo MG. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. Int J Cardiol; doi: 10.1016/j.ijcard.2013.06.036. Published online ahead of print 11 July 2013
42. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M, Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54
43. Gatzoulis MA, Beghetti M, Galiè N, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M. Longer-Term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. Int J Cardiol 2008;127:27-32. (Pubitemid 351707527)
44. Berger RMF, Beghetti M, Galiè N, Gatzoulis MA, Granton J, Lauer A, Chiossi E, Landzberg M. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: A subgroup analysis. Int J Cardiol 2010;144: 373-378
45. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebocontrolled, double-blinded trial. Eur Heart J 2010;31:1124-1131
46. Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome - A randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011;6: 424-431
47. D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012;155:378-82
48. Diller G-P, Alonso-Gonzalez R, Dimopoulos K, Alvarez-Barredo M, Koo C, Kempny A, Harries C, Parfitt L, Uebing AS, Swan L, Marino PS, Wort SJ, Gatzoulis MA. Disease targeting therapies in patients with Eisenmenger syndrome: Response to treatment and long-Term efficiency. Int J Cardiol 2013;167(3):840-7
49. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-Term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: A 2-year study. Heart Br Card Soc 2007;93:350-354. (Pubitemid 46579526)
50. Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, Gatzoulis MA. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121:20-25
51. Sandoval J, Gaspar J, Pulido T, Bautista E, Martínez-Guerra ML, Zeballos M, Palomar A, Gómez A. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998;32:297-304. (Pubitemid 28396475)
52. Oudiz RJ, Midde R, Hovenesyan A, Sun X-G, Roveran G, Hansen JE,Wasserman K. Usefulness of right-To-left shunting and poor exercise gas exchange for predicting prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2010;105: 1186-1191
53. Nootens MT, Berarducci LA, Kaufmann E, Devries S, Rich S. The prevalence and significance of a patent foramen ovale in pulmonary hypertension. Chest 1993;104: 1673-1675
54. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157
55. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-2903
56. Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet 2008;371:2093-2100
57. Inuzuka R, Tatebe S,Wakiguchi S, Nakajima H, Ohtsu H, Dimopoulos K, Aotsuka H. B-Type natriuretic peptide at the early stage of univentricular circulation reflects inadequate adaptation to volume overload. Int J Cardiol 2012;159(2):88-93
58. Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J,Webb GD. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology. Eur Heart J 2010;31:794-805
59. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax 1971;26:240-248
60. de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: A logical alternative to atriopulmonary connection for complex Fontan operations. Experimental studies and early clinical experience. J Thorac Cardiovasc Surg 1988;96: 682-695
61. Alphonso N, Baghai M, Sundar P, Tulloh R, Austin C, Anderson D. Intermediate-Term outcome following the fontan operation: A survival, functional and risk-factor analysis. Eur J Cardio-Thorac Surg 2005;28:529-535. (Pubitemid 41348688)
62. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008;29:1681-1687. (Pubitemid 351957545)
63. Goldberg DJ, French B, Szwast AL, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol 2012;33:689-696
64. Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: A randomized, doubleblind, placebo-controlled, crossover trial. Circulation 2011;123:1185-1193
65. Schuuring MJ, Vis JC, van Dijk APJ, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin-Bon RHACM, Mulder BJM, Bouma BJ. Impact of bosentan on exercise capacity in adults after the Fontan procedure: A randomized controlled trial. Eur J Heart Fail 2013;15:690-698
66. Fukushima H, Kosaki K, Sato R, Yagihashi T, Gatayama R, Kodo K, Hayashi T, Nakazawa M, Tsuchihashi T, Maeda J, Kojima Y, Yamagishi H, Takahashi T. Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A2 and prostacyclin. Am J Med Genet A 2010;152A:1919-1924
67. Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008;177: 1377-1383. (Pubitemid 351860916)
68. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S, Coccolo F, Ventura C, Phillips JA 3rd, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G. Genetic basis of pulmonary arterial hypertension: Current understanding and future directions. J Am Coll Cardiol 2004;43:33S-39S.
69. Therrien J, Rambihar S,Newman B, Siminovitch K, Langleben D,Webb G, Granton J. Eisenmenger syndrome and atrial septal defect: Nature or nurture? Can J Cardiol 2006; 22:1133-1136. (Pubitemid 44932380)
70. D'Alto M, Romeo E, Argiento P, D'Andrea A, Sarubbi B, Correra A, Scognamiglio G, Papa S, Bossone E, Calabrò R, Vizza CD, Russo MG. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. Int J Cardiol 2013;164:323-326
71. Dimopoulos K. Trials and tribulations in adult congenital heart disease. Int J Cardiol 2008;129:160-162
72. Bode-Thomas F. Challenges in the Management of Congenital Heart Disease in Developing Countries. In: Rao PS (ed.) Congenital Heart Disease - Selected Aspects [Internet]. 2012 [cited 23 June 2013]. http://www.intechopen.com/ books/congenital-heart-disease-selected-Aspects/challenges-in-Themanagement-of- congenital-heart-disease-in-developing-countries
73. Leblanc JG. Creating a global climate for pediatric cardiac care.World J Pediatr 2009;5: 89-92
74. Dimopoulos K, Prapa M, Gatzoulis M. Eisenmenger syndromeand other types of pulmonary arterial hypertension related to congenital heart disease. In: Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer; 2013